Literature DB >> 17275620

Perfusion MR imaging and proton MR spectroscopic imaging in differentiating necrotizing cerebritis from glioblastoma multiforme.

Gabriel Pivawer1, Meng Law, David Zagzag.   

Abstract

We describe a lesion with the magnetic resonance imaging (MRI) characteristics of a glioblastoma mutiforme and demonstrate how perfusion MRI and proton MR spectroscopic imaging can be used to differentiate necrotizing cerebritis from what appeared to be a high-grade glioma. A 43-year-old woman presented to her physician complaining of progressive visual disturbance and headache for several weeks. Conventional MRI demonstrated a parietal peripherally enhancing mass with central necrosis and moderate to severe surrounding T2 hyperintensity, suggesting an infiltrating high-grade glioma. However, advanced imaging, including dynamic susceptibility contrast MRI (DSC MRI) and magnetic resonance spectroscopic imaging (MRSI), suggested a nonneoplastic lesion. The DSC MRI data demonstrated no hyperperfusion within the lesion and surrounding T2 signal abnormality, and the MRSI data showed overall decrease in metabolites in this region, except for lactate. Because of the aggressive appearance to the lesion and the patients' worsening symptoms, a biopsy was performed. The pathologic diagnosis was necrotizing cerebritis. After the commencement of steroid therapy, imaging findings and patient symptoms improved. This report will review the utility of advanced imaging for differentiating inflammatory from neoplastic appearing lesions on conventional imaging.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17275620      PMCID: PMC1847362          DOI: 10.1016/j.mri.2006.09.028

Source DB:  PubMed          Journal:  Magn Reson Imaging        ISSN: 0730-725X            Impact factor:   2.546


  10 in total

Review 1.  Intracranial mass lesions: dynamic contrast-enhanced susceptibility-weighted echo-planar perfusion MR imaging.

Authors:  Soonmee Cha; Edmond A Knopp; Glyn Johnson; Stephan G Wetzel; Andrew W Litt; David Zagzag
Journal:  Radiology       Date:  2002-04       Impact factor: 11.105

2.  High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging.

Authors:  Meng Law; Soonmee Cha; Edmond A Knopp; Glyn Johnson; John Arnett; Andrew W Litt
Journal:  Radiology       Date:  2002-03       Impact factor: 11.105

Review 3.  MR spectroscopy of brain tumors.

Authors:  Meng Law
Journal:  Top Magn Reson Imaging       Date:  2004-10

Review 4.  Proton MR spectroscopy of common brain tumors.

Authors:  M Castillo; L Kwock
Journal:  Neuroimaging Clin N Am       Date:  1998-11       Impact factor: 2.264

5.  Serial proton MR spectroscopic imaging of recurrent malignant gliomas after gamma knife radiosurgery.

Authors:  E E Graves; S J Nelson; D B Vigneron; L Verhey; M McDermott; D Larson; S Chang; M D Prados; W P Dillon
Journal:  AJNR Am J Neuroradiol       Date:  2001-04       Impact factor: 3.825

Review 6.  Vasculitis of the nervous system.

Authors:  A Siva
Journal:  J Neurol       Date:  2001-06       Impact factor: 4.849

7.  Gliomas: classification with MR imaging.

Authors:  B L Dean; B P Drayer; C R Bird; R A Flom; J A Hodak; S W Coons; R G Carey
Journal:  Radiology       Date:  1990-02       Impact factor: 11.105

Review 8.  Differentiating surgical from non-surgical lesions using perfusion MR imaging and proton MR spectroscopic imaging.

Authors:  Meng Law; Micole Hamburger; Glyn Johnson; Matilde Inglese; Ana Londono; John Golfinos; David Zagzag; Edmond A Knopp
Journal:  Technol Cancer Res Treat       Date:  2004-12

Review 9.  Central nervous system vasculitis.

Authors:  A Carolei; S Sacco
Journal:  Neurol Sci       Date:  2003-05       Impact factor: 3.307

Review 10.  Vasculitis of the nervous system.

Authors:  David S Younger
Journal:  Curr Opin Neurol       Date:  2004-06       Impact factor: 5.710

  10 in total
  1 in total

1.  Impact of adjuvant chemotherapy for gliomatosis cerebri.

Authors:  Doo-Sik Kong; Sung Tae Kim; Jung-Il Lee; Yeon-Lim Suh; Do Hoon Lim; Won Seog Kim; Ki-Hoon Kwon; Kwan Park; Jong Hyun Kim; Do-Hyun Nam
Journal:  BMC Cancer       Date:  2010-08-13       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.